A Phase II Study of Eribulin in Recurrent or Refractory Osteosarcoma: a report from the Children’s Oncology Group

BACKGROUND: Patients with recurrent or refractory osteosarcoma have a poor prognosis with less than 30% surviving 2 years. Eribulin is a synthetic analog of halichondrin B, has a novel mechanism of action when compared to other microtubule inhibitors and may have anti-tumor activity in osteosarcoma....

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Pediatr Blood Cancer
Main Authors: Isakoff, Michael S., Goldsby, Robert, Villaluna, Doojduen, Krailo, Mark D., Hingorani, Pooja, Collier, Anderson, Morris, Carol D., Kolb, E. Anders, Doski, John J., Womer, Richard B., Gorlick, Richard, Janeway, Katherine A.
Format: Artigo
Sprog:Inglês
Udgivet: 2018
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6501793/
https://ncbi.nlm.nih.gov/pubmed/30378256
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.27524
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker